61 -3 (89) 2026 - Mustafayev T.K. - CLINICAL AND THERAPEUTIC FEATURES OF TREATMENT AND THE STRUCTURE OF COMPLICATIONS IN CHILDREN WITH NEPHROBLASTOMA

CLINICAL AND THERAPEUTIC FEATURES OF TREATMENT AND THE STRUCTURE OF COMPLICATIONS IN CHILDREN WITH NEPHROBLASTOMA

Mustafayev T.K. - Republican Pathologicoanatomic Center of the Republic of Uzbekistan, Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology of the Republic of Uzbekistan

Resume

Relevance. Nephroblastoma is one of the most common malignant tumors in children. Analyzing therapeutic approaches and complications contributes to improving the quality of treatment. Objective. To assess treatment structure, disease stage, and complication rates in children with nephroblastoma. Materials and Methods. Data from 91 children with histologically confirmed nephroblastoma treated at the Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology (2015–2022) were analyzed. Parameters included clinical staging, treatment modalities, chemotherapy protocols, number of courses, and complications. Descriptive statistics and χ² analysis were applied. Results. 66% of patients were under 3 years of age. The most frequently diagnosed stages were 2B and 3A. Combined treatment was administered in 69.2% of cases, primarily using HT+S+HT and S+HT regimens. The most common chemotherapy scheme was CyVADIC. Complication rates increased with multi-stage treatment approaches. Conclusion. Combined therapy is most effective in intermediate stages of nephroblastoma but requires close monitoring for toxicity. Early diagnosis and treatment individualization are critical for improving outcomes.

Keywords: nephroblastoma, children, treatment, chemotherapy, complications, tumor stage.

First page

380

Last page

389

For citation:Mustafayev T.K. - CLINICAL AND THERAPEUTIC FEATURES OF TREATMENT AND THE STRUCTURE OF COMPLICATIONS IN CHILDREN WITH NEPHROBLASTOMA//New Day in Medicine 3(89)2026 380-389 https://newdayworldmedicine.com/en/new_day_medicine/3-89-2026

List of References

  1. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the first National Wilms’ Tumor Study. Cancer. 1990;41(5):1937–1948.
  2. Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015;33(27):2999–3007. doi:10.1200/JCO.2014.59.8223
  3. Green DM, et al. Comparison between the treatment results of the National Wilms Tumor Study and the International Society of Pediatric Oncology. J Clin Oncol. 2001;19(3):871–876. doi:10.1200/JCO.2001.19.3.871
  4. Howard SC, et al. Childhood cancer epidemiology in low-income countries. Cancer. 2008;112(3):461–472. doi:10.1002/cncr.23205
  5. Kalapurakal JA, Perlman EJ, Seibel N, et al. Outcomes of treatment for Wilms tumor with diffuse anaplasia: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2004;22(14):2692–2700. doi:10.1200/JCO.2004.10.082
  6. Pritchard-Jones K, et al. Treatment and outcome of Wilms’ tumour: an international perspective. Pediatr Nephrol. 2016;31(4):623–634. doi:10.1007/s00467-015-3145-6
  7. Spreafico F, Bellani FF. Wilms tumor: Past, present and (possibly) future. Expert Rev Anticancer Ther. 2019;19(9):785–793. doi:10.1080/14737140.2019.1655403
  8. Szychot E, Apps J, Pritchard-Jones K. Wilms’ tumor: biology, diagnosis and treatment. Transl Pediatr. 2014;3(1):12–24. doi:10.3978/j.issn.2224-4336.2014.01.03
  9. Vassal G, Schrappe M, Pritchard-Jones K, et al. Challenges for clinical trials in children and adolescents with cancer. Lancet Oncol. 2016;17(3):e123–e129. doi:10.1016/S1470-2045(15)00543-0
  10. Vujanić GM, et al. The role of biopsy in the diagnosis of renal tumours of childhood: A SIOP RTSG consensus statement. Pediatr Blood Cancer. 2019;66(5):e27653. doi:10.1002/pbc.27653

    file

    download